

Appln. No. 10/630,926
Amd. dated June 19, 2006
Reply to Office Action of January 25, 2006

Amendments to the Claims

This listing of claims will replace all prior versions,
and listings of claims in the application:

Listing of Claims:

Claims 1-2 (Cancelled).

3 (Currently amended). A transgenic mouse having integrated in its genome a nucleic acid construct, comprising a mammalian T-cell lineage specific promoter operably linked to a mammalian Glucocorticoid Induced Leucine-Zipper (GILZ) cDNA sequence, wherein said mouse expresses GILZ in its T-cell lineage at an elevated level compared to a non-transgenic mouse and wherein the expression of GILZ results in a significant decrease in CD4⁺ CD8⁺ double positive cells and increase in CD4⁻ CD8⁻ double negative cells, CD8⁺ single positive cells and CD4⁺ single positive cells when compared with a non-transgenic mouse.

4 (Previously presented). The transgenic mouse according to claim 3, wherein said mammalian T-cell lineage specific promoter comprises a human CD2 promoter and a human CD2 locus control region.

Claims 5-16 (Cancelled).

Appln. No. 10/630,926
Amd. dated June 19, 2006
Reply to Office Action of January 25, 2006

17(Original). A method for screening compounds having glucocorticoid-related effects, comprising:

administering a potential candidate compound to a transgenic mouse of claim 3, and to a control non-transgenic mouse; and

determining whether said potential candidate compound exhibits glucocorticoid-related effects by comparing the effects of the administration of said potential candidate to said transgenic mouse and to said control non-transgenic mouse.

18(Original). A method for screening compounds having glucocorticoid-related effects, comprising:

administering a potential candidate compound to a transgenic mouse of claim 4, and to a control non-transgenic mouse; and

determining whether said potential candidate compound exhibits glucocorticoid-related effects by comparing the effects of the administration of said potential candidate to said transgenic mouse and to said control non-transgenic mouse.

19(Currently amended). A method of producing a transgenic mouse whose genome comprises a nucleic acid construct, wherein said construct comprises a mammalian T-cell lineage specific promoter operably linked to a mammalian Glucocorticoid

Appln. No. 10/630,926
Amd. dated June 19, 2006
Reply to Office Action of January 25, 2006

Induced leucine-Zipper (GILZ) cDNA sequence, said method comprising:

transferring a nucleic acid construct comprising a mammalian T-cell lineage specific promoter operably linked to a mammalian GILZ cDNA sequence to a fertilized mouse oocyte;

allowing the zygote resulting from the fertilized mouse oocyte to develop to term, thereby obtaining a transgenic mouse whose genome comprises the nucleic acid construct;

breeding said transgenic mouse with a non-transgenic mouse to generate offspring; and

selecting from the offspring a transgenic mouse whose genome comprises the nucleic acid construct, wherein said transgenic mouse expresses GILR in the T-cell lineage at an elevated level compared to a non-transgenic mouse and wherein the expression of GILZ results in a significant decrease in CD4⁺ CD8⁺ double positive cells and increase in CD4⁻ CD8⁻ double negative cells, CD8⁺ single positive cells and CD4⁺ single positive cells when compared with a non-transgenic mouse.

Claim 20 (Cancelled).

21 (New). The transgenic mouse of claim 3, wherein said mammalian GILZ cDNA sequence is selected from the group consisting of mouse and human GILZ cDNA sequences.